Publication: Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors
Issued Date
2014-01-01
Resource Type
ISSN
18783686
15356108
15356108
Other identifier(s)
2-s2.0-84907967403
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cancer Cell. Vol.26, No.4 (2014), 479-494
Suggested Citation
Lydia W.T. Cheung, Shuangxing Yu, Dong Zhang, Jie Li, Patrick K.S. Ng, Nattapon Panupinthu, Shreya Mitra, Zhenlin Ju, Qinghua Yu, Han Liang, David H. Hawke, Yiling Lu, Russell R. Broaddus, Gordon B. Mills Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell. Vol.26, No.4 (2014), 479-494. doi:10.1016/j.ccell.2014.08.017 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/33348
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors
Other Contributor(s)
Abstract
© 2014 Elsevier Inc. PIK3R1 (p85α regulatory subunit of PI3K) is frequently mutated across cancer lineages. Herein, we demonstrate that the most common recurrent PIK3R1 mutation PIK3R1R348*and a nearby mutation PIK3R1L370fs, in contrast to wild-type and mutations in other regions of PIK3R1, confers an unexpected sensitivity to MEK and JNK inhibitors invitro and invivo. Consistent with the response to inhibitors, PIK3R1R348*and PIK3R1L370fsunexpectedly increase JNK and ERK phosphorylation. Surprisingly, p85α R348*and L370fs localize to the nucleus where the mutants provide a scaffold for multiple JNK pathway components facilitating nuclear JNK pathway activation. Our findings uncover an unexpected neomorphic role for PIK3R1R348*and neighboring truncation mutations in cellular signaling, providing a rationale for therapeutic targeting of these mutant tumors.